Kamada (KMDA) Stock Price, News & Analysis

Company Overview

Kamada Ltd. is a biopharmaceutical company that focuses on the development, production and commercialization of plasma-derived and recombinant protein therapeutics for the treatment of rare and serious diseases. Headquartered in Rehovot, Israel, the company operates a fully integrated manufacturing facility that spans plasmaderived fractionation, purification, fill/finish and quality control. Kamada’s business model centers on leveraging proprietary purification processes and recombinant protein technologies to deliver therapies with enhanced safety profiles and consistent supply.

The company’s marketed products include Alpha-1 Proteinase Inhibitor (Glassia), indicated for patients with alpha-1 antitrypsin deficiency, and human rabies immunoglobulin (KEDRAB) for post‐exposure prophylaxis of rabies. Kamada has established distribution partnerships in the United States, Europe and other international markets to support the global reach of its commercial portfolio. In addition to finished product supply, the company offers dedicated contract development and manufacturing services (CDMO) for plasmaderived and recombinant proteins.

Alongside its approved therapies, Kamada maintains a clinical pipeline targeting pulmonary and inflammatory disorders. Key investigational programs include AAT for the treatment of rare lung diseases and CMP-001, an immuno‐oncology compound undergoing clinical evaluation. These development efforts are aimed at expanding the company’s footprint in orphan indications where high unmet medical need exists.

Founded in 1990, Kamada has grown from a local start‐up into a Nasdaq‐listed enterprise with operations spanning Israel, North America and Europe. The company’s leadership team combines scientific expertise and commercial experience, guiding Kamada’s strategic collaborations, regulatory activities and market expansion initiatives. Through its integrated platform and focus on specialty proteins, Kamada seeks to deliver long‐term value to patients and stakeholders worldwide.

Key Stats

• Today's Range: $7.77 to $7.88
• 50-Day Range: $6.47 to $7.95
• 52-Week Range: $5.08 to $9.16
• Volume: 23,331 shs
• Average Volume: 96,352 shs
• Market Capitalization: $446.05 million
• P/E Ratio: 26.74
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Moderate Buy

Kamada Stock Analysis - MarketRank™

Kamada scored higher than 79% of companies evaluated by MarketBeat, and ranked 200th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kamada has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Kamada has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 39.13%

Earnings Growth

Earnings for Kamada are expected to grow by 39.13% in the coming year, from $0.23 to $0.32 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kamada is 26.74, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kamada is 26.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.61.

Price to Earnings Growth Ratio

Kamada has a PEG Ratio of 0.96. PEG Ratios around 1 indicate that a company is correctly valued.

Price to Book Value per Share Ratio

Kamada has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.42% of the float of Kamada has been sold short.

Short Interest Ratio / Days to Cover

Kamada has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kamada has recently increased by 168.66%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kamada does not currently pay a dividend.

Dividend Growth

Kamada does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.42% of the float of Kamada has been sold short.

Short Interest Ratio / Days to Cover

Kamada has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kamada has recently increased by 168.66%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

Kamada has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Kamada this week, compared to 2 articles on an average week.

Search Interest

8 people have searched for KMDA on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.

MarketBeat Follows

4 people have added Kamada to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kamada insiders have not sold or bought any company stock.

Percentage Held by Insiders

36.10% of the stock of Kamada is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 20.38% of the stock of Kamada is held by institutions.

KMDA Stock Analysis - Frequently Asked Questions

How have KMDA shares performed this year?

Kamada's stock was trading at $6.09 at the beginning of 2025. Since then, KMDA shares have increased by 27.4% and is now trading at $7.7560.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings results on Wednesday, May, 14th. The biotechnology company reported $0.07 EPS for the quarter, meeting analysts' consensus estimates of $0.07. The biotechnology company earned $44.02 million during the quarter, compared to analyst estimates of $154.06 million. Kamada had a trailing twelve-month return on equity of 6.31% and a net margin of 9.60%.
Read the conference call transcript.

How do I buy shares of Kamada?

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kamada investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), NVIDIA (NVDA), Chipotle Mexican Grill (CMG), ASML (ASML) and Oracle (ORCL).

Company Calendar

• Record date for 4/7 Dividend: 3/17/2025
• Ex-Dividend for 4/7 Dividend: 3/17/2025
• Dividend Payable: 4/07/2025
• Last Earnings: 5/14/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KMDA
• CIK: 1567529
• Web: www.kamada.com
• Phone: (728) 940-6472
• Fax: 972-8940-6473
• Employees: 360
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.00
• High Stock Price Target: $15.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +67.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.29
• Trailing P/E Ratio: 26.74
• Forward P/E Ratio: 33.72
• P/E Growth: 0.96
• Net Income: $14.46 million
• Net Margins: 9.60%
• Pretax Margin: 10.47%
• Return on Equity: 6.31%
• Return on Assets: 4.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.30
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: $160.95 million
• Price / Sales: 2.77
• Cash Flow: $0.48 per share
• Price / Cash Flow: 16.03
• Book Value: $4.51 per share
• Price / Book: 1.72

Miscellaneous

• Outstanding Shares: 57,510,000
• Free Float: 36,746,000
• Market Cap: $446.05 million
• Optionable: Optionable
• Beta: 0.96